IgA NEPHROPATHY INCIDENCE

Primary IgA Nephropathy is a chronic autoimmune disease^4-6

IgA Nephropathy is the most common cause of the primary glomerular diseases that can lead to end-stage renal disease (ESRD).⁶

~2.5/ 100,000

individuals per year suffer from IgAN worldwide⁷

IgA NEPHROPATHY PROGRESSION

Half of patients with IgA Nephropathy may progress to ESRD within 20 years^2,3

*In a retrospective analysis of patients with IgA Nephropathy referred to the Center for Glomerular Diseases at Columbia University Medical Center from 1980 to 2010. Only patients with a biopsy-proven diagnosis and ≥6 months of follow-up were included in outcome analysis (n=126).⁸

^†In a 10-year, long-term follow-up of a cohort of patients (n=149) from the multicenter, open-label, randomized, controlled STOP-IgAN trial. This study represents one of the longest and most rigorously designed IgA Nephropathy studies with the highest evidence currently available.⁹

^‡In a study of adults from central and eastern Kentucky who were diagnosed with IgA Nephropathy (N=251) by renal biopsy between January 1, 1976 and December 31, 2005, which used the National Death Index and United States Renal Data System to establish date of death and date of progression to ESRD.²

IgA Nephropathy is often asymptomatic in early stages. Patients may go undiagnosed until a decline in kidney function has already occurred^6,10

REVEAL A HIDDEN CULPRIT BEHIND IgA NEPHROPATHY

IgA NEPHROPATHY HIDDEN COSTS

IgA Nephropathy progression comes at a high cost.¹¹

According to the American Journal of Managed Care, mean annual costs for patients with ESRD were $121,948 for commercial groups and $87,339 for Medicare groups¹²

Progressive IgA Nephropathy can also have a deep impact on emotional and psychosocial aspects, as well as a patient’s ability to perform physical activities⁶

In the American Journal of Kidney Diseases, the mortality rate in patients with moderate- or high-risk IgAN was twice that of the general population in a large cohort study (N=665) followed for a mean duration of 11.8 years (range: 0.0 to 20.8 years)¹³

Learn about the autoimmune effect in IgAN disease

DISCOVER A PREDOMINANT SOURCE OF IgA NEPHROPATHY

Sign up to be the first to receive all the latest IgA Nephropathy news and updates

Stay connected with Calliditas.

IgA=immunoglobulin A; IgAN=immunoglobulin A Nephropathy; MOD=mechanism of disease.

References: 1. Barratt J, Rovin BH, Cattran D, et al. Kidney Int Rep. 2020;5(20):1620-1624. doi:10.1016/j.ekir.2020.08.009

2. Hastings MC, Bursac Z, Julian BA, et al. Kidney Int Rep. 2017;3(1):99-104. doi:10.1016/j.ekir.2017.08.008

3. Schena FP. Am J Med. 1990;89(2):209-215. doi:10.1016/0002-9343(90)90300-3

4. Barratt J, Feehally J. Semin Nephrol. 2011;31(4):349-360. doi:10.1016/j.semnephrol.2011.06.006

5. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int. 2012;2(suppl 2):259-274.

6. IgA Nephropathy Foundation of America, Inc. The Voice of the Patient: Externally Led Patient-Focused Drug Development Meeting on IgA Nephropathy. https://nkf.egnyte.com/dl/aHGCS6tPNM/?. Accessed August 18, 2021.

7. Penfold RS, Prendecki M, McAdoo S, Tam FWK. Int J Nephrol Renovasc Dis. 2018;11:137-148. doi:10.2147/IJNRD.S129227

8. Arroyo AH, Bomback AS, Butler B, et al. Clin Nephrol. 2015;84(3):145-155. doi:10.5414/CN108556

9. Rauen T, Wied S, Fitzner C, et al; for the STOP-IgAN Investigators. Kidney Int Supp. 2020;98(4):1044-1052. doi:10.1016/j.kint.2020.04.046

10. Lafayette RA, Kelepouris E. Am J Nephrol. 2018;47(suppl 1):43-52. doi:10.1159/000481636

11. United States Renal Data System (USRDS). 2018 USRDS Annual Data Report. Vol 2. 2018; chap 9. Accessed April 7, 2021. https://usrds.org/media/1734/v2_c09_esrd_costs_18_usrds.pdf.

12. Golestaneh L, Alvarez PJ, Reaven N, et al. Am J Manag Care. 2017;23(10 Suppl):S163-S172.

13. Knoop T, Vikse BE, Svarstad E, Leh S, Reisæter AV, Bjørneklett R. Am J Kidney Dis. 2013;62(5):883-890. doi:10.1053/j.ajkd.2013.04.019

14. Ponticelli C, Glassock RJ. Clin J Am Soc Nephrol. 2010;5(12):2363-2372. doi:10.2215/CJN.06720810

15. Ponticelli C, Traversi L, Banfi G. Pediatr Transplant. 2004:8(4):334-338. doi:10.1111/j.1399-3046.2004.00177.x

16. Kiryluk K, Novak J. J Clin Invest. 2014;124(6):2325-2332. doi:10.1172/JCI74475

17. Yeo SC, Cheung CK, Barratt J. Pediatr Nephrol. 2018;33(5):763-777. doi:10.1007/s00467-017-3699-z

18. Jung C, Hugot JP, Barreau F. Int J Inflam. Published online September 19, 2010. doi:10.4061/2010/823710

19. Barratt J, Smith AC, Feehally J. Nephrology (Carlton). 2007;12(3):275-284. doi:10.1111/j.1440-1797.2007.00797.x

20. Boyd JK, Cheung CK, Molyneux K, Feehally J, Barratt J. Kidney Int. 2012;81(9):833-843. doi:10.1038/ki.2011.501

21. Lafayette RA. Transl Res. 2014;163(1):3-7. doi:10.1016/j.trasl.2013.08.007

22. Thompson A, Carroll K, Inker LA, et al. Clin J Am Soc Nephrol. 2019;14(3):469-481. doi:10.2215/CJN.08600718

23. Ibrahim A, Garg AX, Knoll GA, Akbari A, White CA. Am J Transplant. 2013;13(3):708-713. doi:10.1111/ajt.12050

24. Levey AS, Gansevoort RT, Coresh J, et al. Am J Kidney Dis. 2020;75(1):84-104. doi:10.1053/j.ajkd.2019.06.009

25. Goto M, Wakai K, Kawamura T, Ando M, Endoh M, Tomino Y. Nephrol Dial Transplant. 2009;24(10):3068-3074. doi:10.1093/ndt/gfp273

26. Brantsma AH, Atthobari J, Bakker SJ, de Zeeuw D, de Jong PE, Gansevoort RT. J Am Soc Nephrol. 2007;18(2):637-645. doi:10.1681/ASN.2006070738